Showing 1-10 of about 12 articles.
TikaMobile, Inc.
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- TikaMobile, a premier cloud-based business intelligence CRM provider for the life sciences industry, today announced that Titan Pharmaceuticals, Inc. has...
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and...
TikaMobile, Inc.
NEW YORK, May 16, 2018 (GLOBE NEWSWIRE) -- TikaMobile, Inc. a cloud-based analytics and CRM technology company for the life sciences industry, today announced that it was selected to be the business...
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - July 05, 2017) - About 81% of surveyed Top 10, Top 50, and small pharmaceutical and medical device firms build launch sequences from scratch for each...
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - May 10, 2017) - Emerging markets such as Brazil and India are becoming common second wave targets for pharmaceutical product launches, according to a recent...
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - April 05, 2017) - In addition to using medical science liaisons (MSLs) to engage the medical research community, many surveyed pharmaceutical companies have...
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - December 08, 2016) - Contrary to initial misgivings about digital and social channels, they have become an increasingly popular part of healthcare...
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - September 14, 2016) - A recent study found that 74% of surveyed drug companies market new products in the US during their first launch wave. During this same...
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - August 24, 2016) - Although pharmaceutical brand teams do not have the final say on their products' launch sequences, they play an active role in ad hoc...
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - August 18, 2016) - The vast majority (88%) of surveyed pharmaceutical companies do not complete commercial risk assessment activities until Phase 3...
Showing 1-10 of about 12 articles.
